Anticancer Therapies – News and Features

Genzyme provides access to a novel tumor-targeting antibody, and Algeta will provide access to its Thorium platform to attach the alpha emitting payload thorium-227.

Scientific Thought-Leader's move to AVI reflects belief that Company's PMO chemistry is at forefront of delivering the transformative potential of RNA-Based therapeutics.

The study, published in the journal BMC Medical Genomics, elucidates the chemoresistance-associated pathways retrieved from the integrated biological interaction networks and identifies signature genes relevant for chemotherapy resistance.

$36.7 million awarded to investigators to support cancer-related projects and to recruit pre-eminent cancer investigators.

Partnership to help biotechnology and pharmaceutical companies bring next generation oncology therapeutics to market in a more targeted and effective manner.

Five-year extension of the alliance allows both companies to offer unrivalled expertise in cancer research to their pharmaceutical clients.

PIX 306 trial compares a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL.

Company to develop new diagnostics to identify specific subsets of cancer patient populations that would benefit most from receiving DepoVax™-based vaccine therapies.

Clinical trial targets second to fourth line patients with diffuse large B-cell lymphoma.

Kerstin B. Menander has 30-year career in clinical development of novel therapies for cancer and other indications.